March 2022 FDA Recall Janumet by Merck Sharp & Dohme Corp
D-0746-2022 - Presence of foreign substance

This Class II drug recall was voluntarily initiated by Merck Sharp & Dohme Corp on March 31, 2022 for the product Janumet. The FDA reported the reason for recall as presence of foreign substance. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0746-2022

Reason for Recall
Presence of foreign substance: Presence of stainless steel particulates in tablets.
Initiated
03-31-2022
Reported
04-13-2022
Quantity
3600 cartons

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
MERCK SHARP & DOHME CORP
Nationwide in the USA
Janumet (sitagliptin and metformin HCl) tablets, 50 mg/500 mg, 14-count bottle, packaged as 2 bottles per carton , Sample-Not For Sale, Rx Only, Manufactured for Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. Whitehouse Station, NJ 08889, USA, by Patheon Puerto Rico, Inc. Manati, Puerto Rico, 00674 Bottle (NDC 0006-0575-02), Carton (NDC 0006-0575-03)

Batch or Lot Expiration Information

Lot# Lot: U015824, Exp. 09/22.